The British Medical Association (BMA) has performed a significant U-turn by backing the Cass Review, the landmark report on gender identity services within the NHS. However, the doctors' union continues to oppose the government's ban on puberty blockers, asserting that clinical decisions should remain in the hands of medical professionals.
Background of the Cass Review
Published in April 2024 and led by Dr. Hilary Cass, the review concluded that children and young people had been let down by a lack of robust research and evidence regarding medical interventions for gender dysphoria. It described NHS gender medicine as being built on shaky foundations and urged extreme caution when prescribing gender-affirming hormone treatments to minors.
BMA's Shift in Position
Initially, the BMA rejected the Cass Review's findings, labelling them as unsubstantiated. Now, Professor David Strain, chair of the BMA’s board of science and lead author of the new report, has praised Dr. Cass's approach. He told The Times: "She approached an area of significant uncertainty with that prime rule of medicine, of ‘first, do no harm’." Strain further stated that he could not identify a single recommendation among the 32 in the Cass report that the BMA opposed.
Nevertheless, the BMA remains steadfast in its opposition to the government's ban on puberty blockers. The union argues that the ban extends beyond the Cass Review's recommendations and infringes upon doctors' autonomy. In their report, they stated: "We spend decades training on how to use drugs, and to have a political decision affecting the way we prescribe is wrong." Strain emphasised that specialists should be able to prescribe these drugs, but they should not be freely available to all.
Government's Ban and Its Implications
In March, NHS England halted gender-affirming hormone treatment for 16 and 17-year-olds. Previously, such therapy was accessible to adolescents diagnosed with gender dysphoria who met specific criteria. Now, new referrals have been suspended, effectively preventing transgender youths in the UK from accessing puberty blockers. The medication is still prescribed to cisgender children for conditions like precocious puberty.
These hormone treatments can cause irreversible changes, such as breast growth from oestrogen or voice deepening from testosterone. The BMA's stance highlights an ongoing tension between clinical judgment and political intervention in healthcare.
